Many studies have suggested that GC development, treatment, and clinical outcome are associated with variations in several genes, including EGFR [48, 49], glutathione-S-transferase M1 and T1 [50], p53 [51], E-cadherin(CDH1) [52], and cyclooxygenase-2 [53]. This evidence concerns the gene PTGS2 and gastric cancer.